Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samira Reyes Dassum

Infectious Disease Providence, RI Medical Doctor

NPI 1457703720 CMS profile 2381662

50 Maude St, Providence, RI 02908

Open in the dashboard

General payments

$2,135

71 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samira Reyes Dassum of Providence, RI is reported in the CMS Open Payments database as having received $2,135 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $290 6
2024 General $167 2
2023 General $1,020 32
2022 General $150 7
2020 General $251 10
2019 General $258 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samira Reyes Dassum
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Samira Reyes Dassum were reported at $290. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Samira Reyes Dassum Infectious Disease median Middle half National median
2019 $258 $190 $60–$862 $163
2020 $251 $124 $32–$606 $114
2021 $0 $148 $38–$905 $132
2022 $150 $166 $50–$834 $149
2023 $1,020 $171 $57–$787 $160
2024 $167 $176 $52–$752 $164
2025 $290 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $672 14 payments
  2. ViiV Healthcare Company $589 21 payments
  3. AstraZeneca Pharmaceuticals LP $192 11 payments
  4. E.R. Squibb & Sons, L.L.C. $139 7 payments
  5. Phathom Pharmaceuticals, Inc. $122 1 payment
  6. Merck Sharp & Dohme Corporation $110 6 payments
  7. Ferring Pharmaceuticals Inc. $96 3 payments
  8. GlaxoSmithKline, LLC. $83 1 payment
  9. Insmed, Inc. $40 2 payments
  10. Regeneron Healthcare Solutions, Inc. $27 1 payment
  11. Other $66 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,135 71 payments
Products named General payments · program years 2019–2025
  1. DOVATO $490 17 payments
  2. LOKELMA $141 9 payments
  3. VOQUEZNA $122 1 payment
  4. Descovy $117 1 payment
  5. Biktarvy $116 1 payment
  6. REBYOTA $96 3 payments
  7. ELIQUIS $95 5 payments
  8. NUCALA $83 1 payment
  9. DIFICID $79 4 payments
  10. DELSTRIGO $73 4 payments
  11. Other $466 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Internal Medicine: 777

Drug cost

$299

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entecavir Generic 12 $299

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$9,523

Medicare's payments for the services billed

Medicare patients

42

Average age 74

Services billed

100

19 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 57%
Arthritis 50%
Chronic kidney disease 48%
Diabetes 45%
Ischemic heart disease 43%
Heart failure 36%
COPD 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record